| Products | Targets | Indications | Rights | Pre‑clinical | IND | Phase I Clinical Trial | Phase II Clinical Trial | Phase III Clinical Trial |
|---|---|---|---|---|---|---|---|---|
|
HIF-PH
|
Non-dialysis-dependent chronic kidney disease(NDD-CKD)related anemia
|
Global
|
|
|||||
|
Phase II multi-regional trials in China and the US completed
Phase Ⅲ in China ongoing, expected to complete in 2027 H2 Phase III in the US expected to initiate in 2026 H2 |
||||||||
|
HIF-PH
|
Dialysis-dependent chronic kidney disease(DD-CKD)related anemia
|
Global
|
|
|||||
|
Phase II multi-regional trials in China and the US completed
Phase II in China ongoing,expected to completein 2027 H2 |
||||||||
|
HIF-PH
|
Cancer-Related Anemia(CRA)
|
Global
|
|
|||||
|
Phase II in China expected to initiate in 2027 Q3
|
||||||||
|
HIF-PH
|
β-thalassemia
|
Global
|
|
|||||
|
Phase Ⅱ in China ongoing,expected to complete in 2028
|
||||||||
|
HIF-PH
|
Myelodysplastic syndromes (MDS) related anemia
|
Global
|
|
|||||
|
Phase Ⅱ China ongoing,expected to complete in 2028
Phase Ⅱ in the US expected to initiate 2027 H2 |
||||||||
|
HIF-PH
|
Sickle Cell Disease (SCD)
|
Global
|
|
|||||
|
ODD granted by the US FDA
Phase II in the US expected to initiate in 2028H2 |
||||||||
| Products | Targets | Indications | Rights | Pre‑clinical | IND | Phase I Clinical Trial | Phase II Clinical Trial | Phase III Clinical Trial |
|---|---|---|---|---|---|---|---|---|
|
ER
|
ER+/HER2- Breast Cancer
|
Global
|
|
|||||
|
Phase Ia multi-regional trials in China and the US ongoing,
expected to complete in 2026Q4 |
||||||||
|
HIF
|
Renal Cell Carcinoma
|
Global
|
|
|||||
|
Preclinical Research
|
||||||||
|
-
|
AML and solid tumors
|
Global
|
|
|||||
|
Preclinical Research
|
||||||||
|
-
|
Solid tumors
|
Global
|
|
|||||
|
Preclinical Research
|
||||||||
